Christopher Kirkham: Could Platelet Activation Become a Liability for Your Antibody Programme?
Christopher Kirkham, Group Leader in Ex Vivo Biology at IQVIA Laboratories, shared a post on LinkedIn:
“Could platelet activation become a liability for your antibody programme?
Platelet safety is often overlooked until a signal emerges during development. However, unintended interactions with platelets can have significant consequences, including platelet depletion, activation and thrombotic complications.
Early assessment of platelet binding, activation and function can help identify potential liabilities before they become costly development challenges.
At IQVIA Laboratories, we combine flow cytometry and aggregometry to provide a comprehensive ex vivo assessment of antibody-mediated platelet responses, supporting more informed candidate selection and risk assessment earlier in development.”
Stay updated with Hemostasis Today.
-
Aug 1, 2026, 11:07Yashaswi Dhiman: Advancing Hemovigilance Through Award-Winning Science
-
Aug 1, 2026, 08:24Kayla Garrett: Transforming Expectations in Haemophilia A Care
-
Aug 1, 2026, 07:51Toyosi Onwuemene: Are We Measuring the Outcomes That Matter Most to Patients With TTP?
-
Aug 1, 2026, 07:38Danny Hsu: Recognizing Excellence in Scientific Leadership at ISTH 2026
-
Aug 1, 2026, 07:24Ulrich Sachs: A New Strategy to Prevent Platelet Transfusion Refractoriness
-
Aug 1, 2026, 07:12Gijs Aertssen: New Evidence on Joint Prosthesis Survival in Inherited Bleeding Disorders
-
Aug 1, 2026, 06:58Nora Abazi Emini: New Insights into Factor XIII in Atypical Haemolytic Uraemic Syndrome
-
Aug 1, 2026, 06:30Understanding Natural Anticoagulant Deficiencies – JTH
-
Aug 1, 2026, 06:26Fiona Robinson: Webinar – What’s New in Hemophilia A Research?